This study makes use of control group data from the 1958 Birth Cohort and National Blood Service Cohort, which was generated by the Wellcome Trust Case Control Consortium. This data is available from <http://www.wtccc.org.uk> for researchers who meet criteria for access. Regarding control data, readers should follow the application process described here: <http://www.wtccc.org.uk/info/access_to_data_samples.html>. The case group DNA was provided by the Health Protection Agency, which is now part of Public Health England. The materials transfer agreement between Public Health England and Queen's University Belfast means that disclosure of case data requires permission from Public Health England. Regarding the case data, readers should contact the corresponding author, Declan Bradley, at <dbradley09@qub.ac.uk>.

Introduction {#sec005}
============

The complement system is a fundamental part of the innate immune response. This pathway harms unprotected surfaces by a powerful positive feedback cycle that injures cells by perforating them with circular polymers (the membrane attack complex) and by activating further immune response by releasing opsonins and anaphylatoxins \[[@pone.0120757.ref001]--[@pone.0120757.ref003]\]. Complement activation can cause harm to both unprotected self and foreign cell surfaces \[[@pone.0120757.ref001],[@pone.0120757.ref002]\].

Pathogenic bacteria evade the complement system by mimicking or binding to protective host proteins \[[@pone.0120757.ref004]\]. Human complement factor H (CFH) is the major inhibitory regulator of the complement system. Polymorphism of *CFH* and the adjacent homologous *CFHR1--5* genes is associated with susceptibility to several inflammatory diseases \[[@pone.0120757.ref005]--[@pone.0120757.ref010]\]. A genome-wide association study of susceptibility to invasive meningococcal disease identified a major risk association at the *CFH* and *CFHR3* locus \[[@pone.0120757.ref011]\]. The report noted that the associated variants are in strong linkage disequilibrium with the minor allele of rs1065489 (D936E) in the *CFH* gene, but evidence that this is the functional cause is lacking. Unexpectedly, the associated *CFH* polymorphism as one with no known functional effect and is not one associated with other inflammatory diseases.

*Neisseria meningitidis* infection causes sepsis and meningitis, with death in approximately 10% of cases \[[@pone.0120757.ref012]\]. Factor H-binding protein (fHBP) and Neisserial Surface Protein A bind host CFH to protect *N*. *meningitidis* \[[@pone.0120757.ref013]--[@pone.0120757.ref015]\]; *Neisserial* fHBP is critical for meningococcal survival in blood \[[@pone.0120757.ref016]\]. It binds short consensus repeats 6 and 7 of human CFH, which is a region of CFH that also binds to self-surface membranes \[[@pone.0120757.ref017]\]. It may cause its severe systemic effects by sequestering host CFH, leaving self surfaces unprotected \[[@pone.0120757.ref017],[@pone.0120757.ref018]\]. The common CFH Y402H polymorphism (rs1061170), which is a major risk factor for age-related macular degeneration, is adjacent to the fHBP binding site, but does not affect binding to fHBP \[[@pone.0120757.ref017]\].

Factor H binding protein has been a recent focus of interest because it is now a component of vaccines against serogroup B *N*. *meningitidis* \[[@pone.0120757.ref019],[@pone.0120757.ref020]\], one of which is already used in outbreak control \[[@pone.0120757.ref021]\] and is likely to be added to the UK childhood immunisation schedule \[[@pone.0120757.ref022]\], which might result in meningococcal disease becoming rare.

Polymorphism of fHBP can be categorized by two different systems of nomenclature. Fletcher *et al*. use a system of two subfamilies, A and B \[[@pone.0120757.ref019]\]. Masignani *et al*. use a system of three variant groups (1, 2 and 3) \[[@pone.0120757.ref020]\]. Disease severity is associated with polymorphic variation affecting the five segments that make up the modular structure of fHBP \[[@pone.0120757.ref023]--[@pone.0120757.ref025]\]. Previous studies of fHBP sequenced the whole gene from cultured *N*. *meningitidis* isolates, and then defined the subfamily, variant group or modular group using only a small number of sequence features. Our study is the first to define fHBP type directly using DNA isolated from patient blood. This may avoid bias due to variation in the success in culturing different strains of *N*. *meningitidis*.

The aim of this study was to explore the relationship between invasive meningococcal disease and variation of the human complement system. We sought to refine the risk association at the *CFH* locus and to investigate whether variation of *N*. *meningitidis* fHBP affects this association. We explored other variations of the complement system, including terminal pathway genes where deficiency of proteins has been associated with susceptibility to recurrent meningococcal disease \[[@pone.0120757.ref026]--[@pone.0120757.ref029]\] and two complement inhibitors to which *N*. *meningitidis* binds: *CD46*, which encodes membrane cofactor protein, a membrane-bound complement inhibitor \[[@pone.0120757.ref030],[@pone.0120757.ref031]\] and *C4 binding protein*, which inhibits the classical pathway \[[@pone.0120757.ref032]\].

Methods {#sec006}
=======

Ethics Statement {#sec007}
----------------

The study was approved by the Office for Research Ethics Committees Northern Ireland (part of the UK National Research Ethics Service; study reference: 10/NIR03/24). Following formal proposal to its project advisory group, the Health Protection Agency (now part of Public Health England) provided anonymised residual clinical diagnostic DNA samples from PCR-confirmed cases of invasive meningococcal disease collected in 2009 and 2010. No identifying information was provided. Informed consent was not required for these samples because only anonymised demographic data and residual clinical DNA samples were provided. The Wellcome Trust Case Control Consortium (WTCCC) 1958 Birth Cohort and National Blood Service samples were collected with informed consent and used with permission of the WTCCC.

Study Population {#sec008}
----------------

The case population characteristics have been described in detail previously \[[@pone.0120757.ref033]\]. The cases were 309 European individuals with PCR-confirmed invasive meningococcal disease. We did not have access to details of the clinical features or demographic details other than age at time of illness. The *N*. *meningitidis* serogroups were: B, 292; C, 3; W, 4; Y 4. The ages ranged between one month and 73 years, with a median of two years. European ancestry was ascertained by using an ancestry-informative panel of polymorphisms \[[@pone.0120757.ref034]\] and cluster analysis, as described previously \[[@pone.0120757.ref033]\].

The control population comprised 5,200 individuals with European ancestry from the United Kingdom 1958 Birth Cohort and National Blood Service (NBS) cohort, for whom microarray genome-wide data were provided by the Wellcome Trust Case-Control Consortium (WTCCC). The WTCCC exclusions were applied, and validated by principal components analysis, as described previously \[[@pone.0120757.ref033]\]. The case population does not overlap with any group tested in the Davila *et al*. genome-wide association study. The control group is identical to that used in the genome-wide association study \[[@pone.0120757.ref011]\]. The median age of NBS participants was 45 years. The 1958 Birth Cohort participants were aged 52 years at the time of genotyping.

Detection of *N*. *meningitidis* {#sec009}
--------------------------------

Confirmation of invasive meningococcal disease was based on a positive diagnostic Taqman assay for capsular transfer gene (*ctrA*) at the Health Protection Agency (now Public Health England) Meningococcal Reference Unit using an Applied Biosystems 7700 sequence detection system, as described previously \[[@pone.0120757.ref035]\]. The cycle number at which each positive sample was detected was reported. Cycle threshold, which is inversely correlated with bacterial load, has been used as an indicator of disease severity in other studies \[[@pone.0120757.ref036],[@pone.0120757.ref037]\].

Genotyping of *CFH* Polymorphisms {#sec010}
---------------------------------

Six SNPs in *CFH* were genotyped by SNaPshot primer extension methodology, involving PCR to amplify sequence fragments containing polymorphisms of interest, ExoSAP-IT to neutralise unincorporated dNTPs, fluorescent primer extension, further shrimp alkaline phosphatase clean-up, and analysis on an ABI 3100 genetic analyser. The SNPs genotyped were rs1061170 (Y402H), rs800292 (I62V), rs6677604 (which is in full linkage disequilibrium with the deletion of *CFHR3-CFHR1*), rs3753396 (which is in full linkage disequilibrium with rs1065489, D936E), rs419137, and rs2284664. SNPs were chosen on the basis of our established protocols for genotyping \[[@pone.0120757.ref008], [@pone.0120757.ref038]\]. Oligonucleotides are shown in [S1 Table](#pone.0120757.s001){ref-type="supplementary-material"}. Genotype calls were made using GeneMarker v1.5.1. The control dataset had been genotyped on an Illumina 1.2M duo SNP microarray. Four core *CFH* haplotypes were defined using four SNPs ([Table 1](#pone.0120757.t001){ref-type="table"}) based our previous studies (with the very closely related haplotypes 1 and 2 in our haplotype model \[[@pone.0120757.ref038]\] replaced by haplotype A in the present report, defined by rs1061170) \[[@pone.0120757.ref008],[@pone.0120757.ref038]\].

10.1371/journal.pone.0120757.t001

###### *CFH* Haplotype Definitions.

![](pone.0120757.t001){#pone.0120757.t001g}

  Haplotype Name   rs1061170   rs3753396   rs6677604   rs2284664
  ---------------- ----------- ----------- ----------- -----------
  **A**            G           A           G           G
  **B**            A           G           G           G
  **C**            A           A           A           G
  **D**            A           A           G           A

Sequenom iPLEX for complement gene polymorphisms {#sec011}
------------------------------------------------

Polymorphisms of complement pathway genes were investigated using the Sequenom iPLEX platform. PCR and primer extension oligonucleotides were designed using the My Sequenom Online Tools (Sequenom Inc., San Diego, CA, USA), with a target PCR fragment length of between 80 and 120 bp and target primer extension oligonucleotide of between 15 and 30 bases, according to the manufacturer's protocol. Oligonucleotide sequences are shown in [S2 Table](#pone.0120757.s002){ref-type="supplementary-material"}. Shrimp alkaline phosphatase was used to neutralise unincorporated dNTPs after the PCR reaction and the iPLEX Gold resin used for final conditioning after primer extension. The reaction product was nanodispensed onto an array chip by technical staff in the Queen's University Belfast Genome Core using the MassARRAY nanodispenser prior to operation of the MassARRAY mass spectrometer. Genotyping was then carried out using TYPER software (Sequenom). Each SNP cluster plot was inspected individually for quality of clustering and the mass spectrometry plot examined for potentially erroneous base calls, which were recalled or set to missing if a problem was observed. Data were exported from TYPER and converted to PLINK format using Microsoft Excel 2010.

Genotyping of *Neisserial fHBP* {#sec012}
-------------------------------

A method based on the sequence variation described by Pajon *et al*. \[[@pone.0120757.ref023]\] was developed and validated by sequencing *fHBP* from eight cultured isolates of *N*. *meningitidis*. We used a one-step duplex of two PCR reactions in the same experiment. Subfamily A and B fHBP were distinguished by detection of a ten-base insertion/deletion polymorphism in module A of the gene. One pair of primers, one of which was fluorescently Fam-labelled, was used to make a product of either 157 or 167 bases in length, which was detected on the ABI 3100 Genetic Analyser. Further distinguishing between variant 2 and variant 3 was by the use of three sequence-specific primers, all paired with one common, Fam-labelled primer. The three sequence-specific primers were of different lengths, and bound to the junction between modules C and D, each of which may have one of two variants. According to Pajon *et al*., three variants are found, and therefore, the sequence-specific primers were designed to bind to these combinations of polymorphic modules C and D. Oligonucleotide sequences are shown in [S3 Table](#pone.0120757.s003){ref-type="supplementary-material"}. In addition to the subfamily and variant classifications of fHBP, the method can determine the most common modular groups described in Pajon *et al*. \[[@pone.0120757.ref023]\]. The rare (\<0.5%) groups VII, VIII and IX cannot each be distinguished from closely related more common modular groups ([Table 2](#pone.0120757.t002){ref-type="table"}).

10.1371/journal.pone.0120757.t002

###### Subfamily, Variant and Modular fHBP groups.

![](pone.0120757.t002){#pone.0120757.t002g}

  Subfamily                                                            Subfamily A   Subfamily B                  
  -------------------------------------------------------------------- ------------- ------------- ---- ----- --- ----
  **Common Modular Groups**                                            III           VI            II   V     I   IV
  **Rare Modular Groups not differentiated from above by fHBP test**                 VIII          IX   VII       

Statistical Analysis {#sec013}
--------------------

Assessment for deviation from Hardy Weinberg equilibrium was conducted using the method of Wigginton *et al*. \[[@pone.0120757.ref039]\] as implemented in PLINK v1.07 \[[@pone.0120757.ref040],[@pone.0120757.ref041]\]. A *P* value for deviation of \<0.05 in cases, controls, or overall was considered to be significant.

A minimum genotyping rate per SNP of 90% and minimum genotyping rate per individual of 90% were used. Association with individual SNPs was assessed by univariate logistic regression (additive model) in PLINK. Significance for association was accepted at *P* \< 0.05 after Bonferroni correction for multiple testing in the study of the complement pathway. Correction for multiple testing was not used for analysis of *CFH* as this was a replication of a previous report.

Individuals missing genotypes for any of the four *CFH* haplotype-tagging SNPs were excluded from haplotype analysis. Multivariate logistic regression was conducted in SPSS v19 for case-control status using the number of copies of each *CFH* haplotype as covariates, omitting one haplotype (D) as a reference variable to avoid multicollinearity.

Cycle threshold was compared between *CFH* haplotype B carriers and non-carriers using Student's T test in R v3.1.1. Age was compared between fHBP Subfamily A and fHBP Subfamily B using the independent samples median test in SPSS.

Results {#sec014}
=======

CFH {#sec015}
---

The genotyping rate was 99.7%. No markers deviated significantly from Hardy Weinberg equilibrium. Two cases failed genotyping entirely, no other individuals were excluded for incomplete genotyping and no markers were excluded because of low genotyping.

Rs1061170 G was associated with increased risk (OR 1.26 \[95% CI 1.07--1.49\], *P* = 5.3x10^--3^) and rs3753396 G was associated with reduced risk (OR 0.56 \[95% CI 0.43--0.74\], *P* = 3.0x10^--5^) ([Table 3](#pone.0120757.t003){ref-type="table"}). Multivariate logistic regression shows that haplotype B, tagged by rs3753396 G, is significantly associated with a reduced odds ratio of invasive meningococcal disease (OR 0.56 \[95% CI 0.42--0.76\], *P* = 1.6x10^--4^) ([Table 4](#pone.0120757.t004){ref-type="table"}). Haplotype C, which carries the deletion of *CFHR3* and *CFHR1* \[[@pone.0120757.ref008]\] was not associated with the phenotype.

10.1371/journal.pone.0120757.t003

###### Association between *CFH* SNPs and IMD.

![](pone.0120757.t003){#pone.0120757.t003g}

  SNP         Allele 1   Allele 1 Frequency in Cases   Allele 1 Frequency in Controls   Allele 2   Number of cases   Number of controls   Odds Ratio (95% Confidence Interval)   *P*
  ----------- ---------- ----------------------------- -------------------------------- ---------- ----------------- -------------------- -------------------------------------- ------------
  rs800292    A          0.26                          0.23                             G          307               5199                 1.16 (0.96--1.40)                      0.13
  rs1061170   G          0.43                          0.38                             A          306               5124                 1.26 (1.07--1.49)                      5.3x10^−3^
  rs6677604   A          0.19                          0.20                             G          307               5190                 0.95 (0.77--1.17)                      0.61
  rs3753396   G          0.10                          0.17                             A          304               5196                 0.56 (0.43--0.74)                      3.0x10^−5^
  rs419137    C          0.15                          0.13                             A          307               5200                 1.22 (0.97--1.53)                      0.09
  rs2284664   A          0.23                          0.21                             G          307               5199                 1.14 (0.94--1.38)                      0.20

10.1371/journal.pone.0120757.t004

###### Additive Model Multivariate Logistic Regression for *CFH* haplotype and IMD.

![](pone.0120757.t004){#pone.0120757.t004g}

                                  Odds Ratio          *P*
  ------------------------------- ------------------- ------------
  Haplotype A (rs1061170 \[G\])   1.06 (0.87--1.29)   0.57
  Haplotype B (rs3753396 \[G\])   0.56 (0.42--0.76)   1.6x10^−4^
  Haplotype C (rs6677604 \[A\])   0.89 (0.70--1.15)   0.37

The cycle threshold for *CtrA* in haplotype B carriers was 31.4 and for 'wild-type' non-carriers was 31.3.

Factor H-Binding Protein Characteristics in the Case Population {#sec016}
---------------------------------------------------------------

The frequencies of the *Neisserial* fHBP variants are shown ([Table 5](#pone.0120757.t005){ref-type="table"}). These are similar to those reported by Pajon *et al*.\[[@pone.0120757.ref023]\].

10.1371/journal.pone.0120757.t005

###### fHBP Variant Frequencies in the Case Population.

![](pone.0120757.t005){#pone.0120757.t005g}

  fHBP Module Group        Present Study Number (frequency)   Pajon\[[@pone.0120757.ref023]\] Number (frequency)
  ------------------------ ---------------------------------- ----------------------------------------------------
  I/VII                    129 (0.52)                         126 (0.52)
  II/VIII                  7 (0.03)                           21 (0.09)
  III                      12 (0.05)                          26 (0.11)
  IV                       54 (0.22)                          12 (0.05)
  V/IX                     24 (0.10)                          32 (0.13)
  VI                       20 (0.08)                          25 (0.10)
  Total                    246                                242
  **fHBP Variant Group**                                      
  1                        183 (0.74)                         138 (0.57)
  2                        32 (0.13)                          51 (0.21)
  3                        31 (0.13)                          53 (0.22)
  Total                    246                                242
  **fHBP Subfamily**                                          
  A                        71 (0.26)                          104 (0.43)
  B                        198 (0.74)                         138 (0.57)
  Total                    269                                242

The median age of cases with subfamily A fHBP *N*. *meningitidis* was one year and that of cases with subfamily B fHBP *N*. *meningitidis* was two years (independent-samples median test *P* = 0.025). The mean cycle threshold for detection of *ctrA* for cases with subfamily A fHBP *N*. *meningitidis* was 29.7 and that for subfamily B fHBP *N*. *meningitidis* was 29.2.

Susceptibility to *N*. *meningitidis* with Subfamily A and Subfamily B fHBP {#sec017}
---------------------------------------------------------------------------

*CFH* Haplotype B was associated with a statistically significant protective effect against the rarer subfamily A *fHBP*-expressing *N*. *meningitidis* infection, but was not associated with protection against the more common subfamily B fHBP-expressing *N*. *meningitidis* ([Table 6](#pone.0120757.t006){ref-type="table"}). However, there was no significant difference between the distribution of fHBP subfamily *N*. *meningitidis* infection in haplotype B heterozygote cases and wild-type homozygote cases (Pearson chi-square *P* = 0.11; [Table 7](#pone.0120757.t007){ref-type="table"}).

10.1371/journal.pone.0120757.t006

###### Association of *CFH* Haplotypes with Susceptibility to Invasive Infection with *N*. *meningitidis* expressing Subfamily A and Subfamily B fHBP.

![](pone.0120757.t006){#pone.0120757.t006g}

                                Subfamily A fHBP    Subfamily B fHBP                       
  ----------------------------- ------------------- ------------------ ------------------- ------
  Haplotype A \[rs1061170 G\]   1.31 (0.83--2.05)   0.25               1.03 (0.78--1.36)   0.83
  Haplotype B \[rs3753396 G\]   0.46 (0.22--0.98)   0.046              0.72 (0.50--1.06)   0.09
  Haplotype C \[rs6677604 A\]   0.99 (0.56--1.74)   0.98               0.91 (0.65--1.28)   0.59

10.1371/journal.pone.0120757.t007

###### Direct Comparison of Subfamily of Haplotype B Heterozygotes and Non-Heterozygotes (Wild-type).

![](pone.0120757.t007){#pone.0120757.t007g}

                             Subfamily A   Subfamily B
  -------------------------- ------------- -------------
  Haplotype B Heterozygote   9             42
  Wild-type Homozygote       49            120

Complement Pathway {#sec018}
------------------

Twenty nine individuals were excluded because of a low genotyping rate, and no SNPs were excluded because of low genotyping leaving 281 cases and 5,199 controls. The remaining genotyping rate was 99.8%. Five SNPs were excluded due to significant deviation from Hardy Weinberg equilibrium in controls, all of which were in *CD46*.

One SNP in each of *CD46* (rs2796278), *C5* (rs17216529), *C8A* (rs17300936) and *C8B* (rs12085435) was associated with the phenotype before correction for multiple testing ([Table 8](#pone.0120757.t008){ref-type="table"}). The association with rs12085435 in *C8B* was significant after Bonferroni correction for 21 tests (*P* = 0.03), and the other SNP associations were non-significant. Both *C8* SNPs were independently associated with the disease phenotype in multivariate logistic regression ([Table 9](#pone.0120757.t009){ref-type="table"}).

10.1371/journal.pone.0120757.t008

###### Sequenom iPLEX of Complement Pathway Genes in IMD.

![](pone.0120757.t008){#pone.0120757.t008g}

  Chromosome   Position(NCBI b37)   SNP Name     Gene      Change   Allele 1   Cases   Controls   Allele 2   Odds Ratio (95% CI)   P
  ------------ -------------------- ------------ --------- -------- ---------- ------- ---------- ---------- --------------------- ------------
  1            57064136             rs947636     *C8A*              C          0.32    0.29       T          1.15 (0.96--1.38)     0.14
  1            57113315             rs652785     *C8A*     Q\>K     T          0.42    0.38       G          1.19 (1.00--1.41)     0.06
  1            57155946             rs17300936   *C8A*     P\>L     A          0.09    0.13       G          0.67 (0.50--0.89)     6.2x10^−3^
  1            57180072             rs626457     *C8B*              A          0.34    0.33       G          1.04 (0.87--1.25)     0.67
  1            57187898             rs12085435   *C8B*     P\>L     A          0.02    0.05       G          0.35 (0.19--0.67)     1.3x10^−3^
  1            57195072             rs1013579    *C8B*     G\>R     G          0.03    0.03       A          0.96 (0.58--1.61)     0.89
  1            57195099             rs12067507   *C8B*     E\>K     T          0.04    0.05       C          0.71 (0.46--1.10)     0.13
  1            205356059            rs2842704    *C4BPA*            C          0.14    0.14       T          1.03 (0.80--1.32)     0.83
  1            205360403            rs4425986    *C4BPA*            C          0.44    0.43       T          1.05 (0.88--1.25)     0.58
  1            205364303            rs1126618    *C4BPA*   G\>G     T          0.17    0.16       C          1.06 (0.84--1.33)     0.61
  1            205371523            rs4844573    *C4BPA*   I\>T     C          0.32    0.35       T          0.90 (0.75--1.08)     0.26
  1            205372211            rs4571969    *C4BPA*            T          0.24    0.24       C          1.00 (0.82--1.23)     0.99
  1            206022446            rs2796278    *CD46*             C          0.54    0.49       A          1.25 (1.05--1.48)     0.01
  5            39285479             rs155375     *C9*               T          0.43    0.44       C          0.96 (0.81--1.13)     0.61
  5            39400311             rs700233     *C9*      R\>W     A          0.37    0.40       G          0.88 (0.74--1.05)     0.16
  5            40998620             rs10941528   *C7*               A          0.23    0.23       G          1.01 (0.83--1.24)     0.90
  5            41001075             rs3805221    *C7*               T          0.23    0.24       C          0.99 (0.81--1.21)     0.89
  5            41021361             rs4957361    *C7*               T          0.35    0.36       C          0.98 (0.82--1.17)     0.79
  5            41235716             rs1801033    *C6*      A\>E     C          0.35    0.37       A          0.94 (0.79--1.13)     0.52
  9            122765747            rs17612      *C5*      E\>D     C          0.06    0.08       A          0.74 (0.51--1.06)     0.10
  9            122840039            rs17216529   *C5*      V\>I     A          0.04    0.07       G          0.55 (0.36--0.84)     5.6x10^−3^

10.1371/journal.pone.0120757.t009

###### Multivariate logistic regression of rs17300936 and rs12085435.

![](pone.0120757.t009){#pone.0120757.t009g}

  SNP            OR (95% CI)         P
  -------------- ------------------- ------------
  rs17300936 A   0.65 (0.48--0.88)   5.4x10^−3^
  rs12085435 A   0.34 (0.18--0.64)   8.4x10^−4^

Discussion {#sec019}
==========

Our study explored the characteristics of the association between meningococcal disease and *CFH* polymorphism, the relationship between fHBP subfamily and this association and the effects of other polymorphisms of complement system genes on disease risk.

Our findings provide further evidence supporting the association between *CFH* polymorphism and invasive meningococcal disease reported by Davila *et al*. \[[@pone.0120757.ref011]\] but as we used the same control group as that study, this is not a full independent replication of the finding. Haplotypic exploration revealed that the association is due to only one haplotype (B), which does not carry any of the known major functional variants associated with AMD. The haplotypes that carry deletion of *CFHR3-CFHR1* (haplotype C) and Y402H (haplotype A) were not associated in a multivariate logistic regression. The protective haplotype B was not associated with any difference in the bacterial load (measured by cycle threshold), suggesting that while disease risk is altered by carrying this variant, severity of disease is not. There was no significant difference in age of cases between carriers and non-carriers of haplotype B, suggesting that the protective mechanism does not affect the age of onset.

There was no significant difference between the distribution of the fHBP subfamilies in individuals who have a copy of *CFH* haplotype B and those who do not, which suggests that *CFH* haplotype variation does not alter the risk of infection with meningococci with fHBP subfamilies A and B differently.

The patients affected by *N*. *meningitidis* with fHBP subfamily A were significantly younger than those who had infection with *N*. *meningitidis* with fHBP subfamily B.

Our investigation of other complement pathway polymorphisms suggests that that a coding polymorphism in *C8B* may be associated with susceptibility to invasive meningococcal disease. This is consistent with the observation that terminal complement component deficiencies increase risk of invasive meningococcal disease \[[@pone.0120757.ref042]\]. This possibility requires replication in an independent cohort.

Our study is unique in integrating human and bacteriological genomic information to assess the effects of variation of genes that produce interacting proteins. The most important limitation of this study is the lack of an independent replication group to confirm the association at *C8B*. Our study used the same control group as Davila *et al*. \[[@pone.0120757.ref011]\], meaning that we have not reported a full independent replication of the association at *CFH*. We conducted our own laboratory experiments to genotype meningococcal disease cases and compared them to controls that were genotyped using a different method, at a different time. This presents risk of a systematic genotyping error that could result in a false association. Independent replication is therefore vital. The exploration of the effect of *CFH* haplotype on disease severity (indicated by *CtrA* cycle threshold) and of *fHBP* on severity and age, are not affected by these limitations because these are analyses of cases only.

The functional basis for the relationship between *CFH* polymorphism and susceptibility to invasive meningococcal disease is not yet understood: It is likely that it relates to the interaction between CFH or CFH-related proteins and *N*. *meningitidis*. As meningococcal disease becomes less common, the focus of research may change to questions of immunity and vaccination: It would be most interesting to understand whether vaccine fHBP interacts differently with different variants in host CFH and CFHR proteins following vaccination in humans, and whether vaccination results in complement activation through transient sequestration of CFH. Costa *et al*. recently suggested that fHBP with low affinity for CFH should be explored in future development of fHBP-based vaccines to increase immunogenicity and reduce the chance of autoantibody formation to CFH \[[@pone.0120757.ref043]\]. It is conceivable that carriage of the protective *CFH* haplotype could influence the effectiveness or side-effects of the vaccine, such as fever, which is common following meningococcal B vaccination \[[@pone.0120757.ref044]\].

The association between *C8B* rs12085435 and risk of meningococcal disease in our study is in keeping with the effect of inherited terminal complement deficiencies on susceptibility to meningococcal disease \[[@pone.0120757.ref042]\]. Independent replication will be key to establishing whether *C8B* is a second complement gene associated with meningococcal disease risk.
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